Drug Topics January 18, 2024
Denise Myshko

In 2023, the FDA approved six vaccines, including 2 for respiratory syncytial virus (RSV), and the first vaccine to prevent the mosquito-borne virus chikungunya.

Vaccinations are one of the most important public health efforts for preventing serious illness, avoiding hospitalizations and saving lives. During the COVID-19 pandemic, vaccine technology made a huge leap forward with the introduction of messenger RNA (mRNA) vaccines. COVID-19 vaccines developed by BioNTech/Pfizer and Moderna use mRNA instead of weakened viruses or virus fragments to teach the body’s immune system how to respond when presented with an infection.

Innovation in the vaccine area continues. In 2023, the FDA approved six vaccines, including several important firsts. (See list below.)

In the area of respiratory diseases, the first...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Common Trends in GLP-1 Use Amid Increased Indications
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more

Share This Article